The Latest Breaking News on Pharma

Respiratory Syncytial Virus is the leading cause of infant hospital admissions in the UK.

Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off. However, the company is advancing its drug candidates via research breakthroughs, clinical trials, and strategic initiatives. Given the company’s constant progress, can this biotech…

NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring

We need to consider a vaccine strategy that will provide longer-term immunity

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

An Australian-first clinical trial for a new needle-free COVID-19 vaccine has begun on the Sunshine Coast, in good news for those who fear the jab.

Chief financial officer David Denton reportedly told investors at the drug maker that he expects profits will continue to rise

Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Research suggests the drug, called Evusheld, would be 88% effective at preventing intensive care admission for people with weakened immune systems still shielding from Covid because vaccines don't work for them.

SAN JOSE, Calif. — Bay Area tech and biotech companies have recently revealed plans to chop thousands of jobs, layoffs that raise the specter that these cutbacks might haunt the region’s broader economy.